Dulaglutide Biosimilar Achieves Equivalent Efficacy in HbA1c Reduction in Patients With T2DM - Prabadin Corp

https://prabadinews.com/

Email

weborders@prabadincorp.com

Call us

+1 (786)-332-3938

Dulaglutide Biosimilar Achieves Equivalent Efficacy in HbA1c Reduction in Patients With T2DM

Medical Supplies

August 22, 2025

By AdminPrabadin - 1 week ago

0

A new biosimilar, LY05008, shows comparable efficacy and safety to dulaglutide in managing type 2 diabetes mellitus (T2DM) in Chinese adults.

administrator